Presentation is loading. Please wait.

Presentation is loading. Please wait.

Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: An open-label pilot.

Published byMerry Stevens Modified over 5 years ago

Similar presentations

Presentation on theme: "Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: An open-label pilot."— Presentation transcript:

1 Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: An open-label pilot study  Yasuo Kubota, MD, Kozo Yoneda, MD, Kozo Nakai, MD, Junko Katsuura, MD, Tetsuya Moriue, MD, Yoshie Matsuoka, MD, Izumi Miyamoto, MD, Yukihiro Ohya, MD  Journal of the American Academy of Dermatology  Volume 60, Issue 2, Pages (February 2009) DOI: /j.jaad Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Schematic presentation of topical sequential therapy and data-sampling periods using Eczema Area and Severity Index, pruritus and sleep disturbance scores, and quality-of-life (QOL) survey. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Change from baseline to end of treatment (for up to 12 weeks) in Eczema Area and Severity Index (EASI) scores in pediatric patients with atopic dermatitis. Significant improvement was observed throughout the course of sequential therapy (P < .001). Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

4 Fig 3 Change from baseline to end of treatment (12 weeks) in patients' assessment of pruritus (A) and sleep disturbance (B) in pediatric patients with atopic dermatitis. Significant improvement was observed throughout the course of sequential therapy (P < .001). Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

5 Fig 4 Clinical improvement of patient before (A) and after (B) 10 weeks of sequential therapy with tacrolimus ointment 0.03% and corticosteroid ointment (betamethasone valerate 0.12%). Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

6 Fig 5 A, Children's Dermatology Life Quality Index (CDLQI). B, Infant's Dermatology Quality of Life (QOL) Index (IDQOL). QOL change scores from baseline to end of treatment (at maintenance phase). Significant improvement of QOL was observed throughout the course of sequential therapy (P < .05). Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

7 Fig 6 A, Children's Dermatology Life Quality Index (CDLQI). B, Infant's Dermatology Quality of Life Index (IDQOL). Topical sequential therapy significantly improved areas in which atopic dermatitis has greatest impact, including symptoms/feelings (CDLQI, IDQOL) and sleep disturbance (CDLQI). Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

8 Fig 7 Median difference between pretest (quality-of-life score before study) and retrospective pretest scores was significant at group level (P < .05), indicating that response shift bias was present. CDLQI, Children's Dermatology Life Quality Index. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: An open-label pilot."

Similar presentations

Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice  Jorien van der Schaft, MD, PhD, Lieneke F.M. Ariens,

Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice  Jorien van der Schaft, MD, PhD, Lieneke F.M. Ariens,
Molluscum contagiosum infection during the treatment of vitiligo with tacrolimus ointment  Bong Kyun Ahn, MD, Byoung-Dae Kim, MD, Sang Ju Lee, MD, Seung.

Molluscum contagiosum infection during the treatment of vitiligo with tacrolimus ointment  Bong Kyun Ahn, MD, Byoung-Dae Kim, MD, Sang Ju Lee, MD, Seung.
Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients  Lily Chen, BA, Feng Gao, MD, PhD, MPH,

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients  Lily Chen, BA, Feng Gao, MD, PhD, MPH,
Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients  Lucy Y. Liu, BA, Brittany.

Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients  Lucy Y. Liu, BA, Brittany.
Use of Eczema Action Plans (EAPs) to improve parental understanding of treatment regimens in pediatric atopic dermatitis (AD): A randomized controlled.

Use of Eczema Action Plans (EAPs) to improve parental understanding of treatment regimens in pediatric atopic dermatitis (AD): A randomized controlled.
A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children  Mark Boguniewicz, MDa, Virginia C. Fiedler,

A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children  Mark Boguniewicz, MDa, Virginia C. Fiedler,
Baldness reversed by chemotherapy

Baldness reversed by chemotherapy
Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 
Ahmad Al Aboud, MD, Melissa Abrams, MD, Anthony J. Mancini, MD 

Ahmad Al Aboud, MD, Melissa Abrams, MD, Anthony J. Mancini, MD 
Efficacy of simvastatin in plaque psoriasis: A pilot study

Efficacy of simvastatin in plaque psoriasis: A pilot study
Hypertrichosis around a leg ulcer being treated with prostaglandin E1 ointment  Tetsuya Honda, MD, PhD, Satoshi Koreeda, MD, PhD, Yoshiki Miyachi, MD,

Hypertrichosis around a leg ulcer being treated with prostaglandin E1 ointment  Tetsuya Honda, MD, PhD, Satoshi Koreeda, MD, PhD, Yoshiki Miyachi, MD,
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
Shawn G. Kwatra, BS, Hong Liang Tey, MRCP (UK), Saba M

Shawn G. Kwatra, BS, Hong Liang Tey, MRCP (UK), Saba M
Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice  Jorien van der Schaft, MD, PhD, Lieneke F.M. Ariens,

Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice  Jorien van der Schaft, MD, PhD, Lieneke F.M. Ariens,
María Jesús Suárez Valladares, MD, Manuel Ángel Rodríguez Prieto, MD 

María Jesús Suárez Valladares, MD, Manuel Ángel Rodríguez Prieto, MD 
Surveillance and assessment of occupational dermatitis using Rhode Island workers' compensation data 1998 to 2002  Irwin B. Horwitz, PhD, Brian P. McCall,

Surveillance and assessment of occupational dermatitis using Rhode Island workers' compensation data 1998 to 2002  Irwin B. Horwitz, PhD, Brian P. McCall,
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

Similar presentations

Ads by Google